Investor Presentaiton
State-of-the-art Manufacturing Facilities Designed to, Built with,
and Operating at International Standards
R&D Labs
Total capacity in the future: 60,000 L
36,000L
Warehouse
24,000L
QC labs
Innovent
Administration
Innovent
• Manufacturing facilities (a total of 24,000L bioreactors) received cGMP certification from the NMPA for manufacturing TYVYTⓇ
(sintilimab) as well as three biosimilar products
Additional 36,000L capacity expected to complete construction and validation in 2021
Facilities were designed to meet FDA, EMA,
PMDA and NMPA standards, and support
the full process from DS to DP. DS, DP and
GMP were successfully audited
Facilities have undergone ordinary course,
comprehensive annual audits to evaluate
compliance with industry cGMP and
quality compliance standards
Manufacturing team has extensive experience
at multi-national bio-pharmaceutical
companies
Confidential
Copyright©2021 Innovent Biologics
10
InnoventView entire presentation